Neoadjuvant Immunotherapy for Liver Cancer: Shrinking Tumors, Growing Responses
Treating seemingly inoperable liver tumors with neoadjuvant immunotherapy may make surgery more feasible.
Progress Against Cancer
Treating seemingly inoperable liver tumors with neoadjuvant immunotherapy may make surgery more feasible.
Changes to sexual health during breast cancer treatment can impact quality of life and treatment adherence—especially in Black women.
Expanded dependent coverage improves cancer outcomes in young adults, and breast cancer treatment can lead to faster cell aging.
The PI3K inhibitor is approved as part of combination therapy for certain patients whose breast cancer recurred on or after endocrine therapy. The U.S. Food and Drug Administration (FDA) approved inavolisib (Itovebi), in combination...
Study finds people who receive brain radiation often recover cognitive abilities over time, and report details breast cancer trends.
The immunotherapy is now approved to treat certain lung cancers before and after surgery. The U.S. Food and Drug Administration (FDA) has approved neoadjuvant nivolumab (Opdivo) with platinum-containing chemotherapy, followed by adjuvant nivolumab alone,...
Several recent studies, including on presented at the AACR Conference on the Science of Cancer Health Disparities, have examined the ACA's impact on access to cancer care.
Adding MRI to prostate screening can help limit overdiagnosis, and breast cancer patients who smoke have a higher risk of radiotherapy-related lung cancer.
The accelerated approval of selpercatinib for certain patients with thyroid cancer was converted to a full approval. The U.S. Food and Drug Administration (FDA) has granted full approval to selpercatinib (Retevmo) for patients 2...
This month, AACR's journals editors highlighted factors that may reduce pancreatic cancer risk, a new humanized mouse model, and more.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More